This article is more than 5 years old. Information may no longer be current.

FDA approves Humira for treatment of noninfectious intermediate, posterior and panuveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved Humira for the treatment of noninfectious intermediate and posterior uveitis and panuveitis, according to a press release from AbbVie.

With this approval, the company now has 10 approved indications for Humira (adalimumab) in the U.S. for immune-mediated diseases.

In June, the European Commission approved Humira for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. In the U.S., this is the first non-corticosteroid treatment available for these indications.

The approval was based on the phase 3 VISUAL-I and VISUAL-II studies, which showed adult patients with noninfectious intermediate and posterior uveitis and panuveitis treated with Humira had a significantly lower risk of uveitic flare and decreased visual acuity compared with placebo.